STOKStoke Therapeutics, Inc.
$24.71+7.9% 1Y
$24.71
$22.3752 weeks$38.35
Is the business good?
Mixed
1 neutral, 3 without dataMargins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is STOK?
Stoke Therapeutics, Inc. keeps −810% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
−810%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +13%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 611%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2022 | −841% |
| FY2023 | −1307% |
| FY2024 | −277% |
| FY2025 | −11% |
Details›
- Operating margin12 months to Q2 2026
- −810%
- Net margin12 months to Q2 2026
- −754%
- Free cash flow margin
- −655%
- R&D as % of revenue
- 611%
- Revenue, trailing twelve months
- $28M
- Free cash flow, trailing twelve months
- −$181M
- Net income, trailing twelve months
- −$208M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks